Published in Cancer Weekly, March 8th, 2005
For the second fiscal quarter, ended December 31, 2004, predictive medicine revenues grew to a record $17.5 million from $10.4 million for the same quarter last year, a $7.1 million, or 68% increase. Compared with the first fiscal quarter of 2005, predictive medicine revenues were up $3.1 million, or 22%.
The company believes that this significant increase in predictive medicine revenues resulted from strong customer demand for Myriad's predictive medicine products due in part to the increased clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.